Introduction
Despite recent advances in the treatment of metastatic colorectal cancer (mCRC), it is still the most frequent gastrointestinal system cancer in the western countries, with being an important cause of cancer mortality, affecting approximately 746.000 men and 614.000 women each year (1) . Colorectal cancer is the third most common cancer worldwide and the second most common cause of cancer-related deaths in the United States (US), with 20% to 30% of patients having synchronous metastatic disease at the time of presentation and more than half of the patients eventually developing metastatic disease with unresectable metastases (2) . After the introduction of chemotherapeutic agents such as fluoropyrimidines, oxaliplatine, and irinotecan along with monoclonal antibodies targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR), median overall survival (OS) duration of mCRC patients has improved approximately 30 months over the last 20 years (3) , with a great extent of this progress being due to molecular targeted therapies, such as anti-angiogenic agents (bevacizumab) or EGFR signaling pathway inhibitors (cetuximab and panitumumab) (4) .
Regorafenib, a novel oral multi-kinase inhibitor, has demonstrated antitumor activity in patients with mCRC who were previously treated with fluoropyrimidine-, oxaliplatine-and irinotecan-based chemotherapy +/-anti-VEGF therapy or anti-EGFR therapy through inhibiting a very diverse range of oncogenic gene products and growth factor receptors including KIT, RET, RAF1, BRAF, BRAFV600E, VEGFR, platelet-derived growth factor receptor PDGFR and fibroblast growth factor receptors (FGFR), hence being approved by FDA 2012 for use as monotherapy as last-line setting (5, 6) . Anti-tumor activity and survival benefit of regorafenib were previously shown in two large randomized placebo-controlled trials, CORRECT (7) and CONCUR (8) , which were performed in mCRC patients progressing on standard therapies. Survival benefit and efficacy of regorafenib were also confirmed by the large European REBECCA (9) cohort study in a real-world setting, with a similar toxicity profile as seen in previous randomized studies mentioned above.
Here, we performed a multicenter retrospective study to evaluate the efficacy and toxicity profile of regorafenib in mCRC patients in Turkey.
Methods
From October 2015 to December 2017, a total of 23 consecutive Turkish patients from two major centers receiving regorafenib monotherapy for refractory mCRC as third-line setting were analyzed. Patients with histologically confirmed mCRC were included in the study. The study was approved by the Necmettin Erbakan University Local Ethics Committee (Decision No. 2018/1319). This retrospective study was designed in accordance with the World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects", amended in October 2013. Since it was a retrospective study, no patient consent form could be obtained. We conducted a retrospective multicenter study to assess the efficacy and toxicity profile of regorafenib in mCRC, patients who were previously treated with fluoropyrimidine-, oxaliplatine-and irinotecan-based chemotherapy +/-anti-VEGF therapy (e.g. bevacizumab, ziv-aflibercept) or anti-EGFR (e.g. panitumumab, cetuximab) when appropriate. Baseline data of all patients, including disease characteristics, patient demographics, laboratory parameters, performance status (PS), treatments, response to treatments, and toxicities were carefully recorded.
After the failure of standard therapies, regorafenib was initiated as a monotherapy at 160 mg daily dose for 21 days with a 28-day repeating cycle. At the discretion of the physicians, a lower initial dose was allowed depending on the patient's clinical condition, and then the dose was increased by 40 mg per week until the maximum dose of 160 mg, relying on the patient's tolerability.
Evaluation of treatment responses was performed every 3 months by computed tomography (CT) or positron emission tomography (PET)-CT using the Response Evaluation Criteria in Solid Tumor version 1.1. National Cancer Institute Common Terminology Criteria of Adverse events version 4.0 was used to grade the adverse events. Dose reduction was allowed in case of drug intolerance or ≥ grade 3 toxicity. Regorafenib was given until disease progression, unacceptable toxicity or patient's withdrawal.
Statistical Analysis
All statistical analyzes were performed using Statistical Package for Social Sciences version 21.0 for Windows (SPSS, Inc. Chicago, IL, USA). Descriptive statistics were reported as percentage and median. Survival data were analyzed according to the Kaplan-Meier Method and were compared using Log-rank statistics. P value less than 0.05 was considered as statistically significant. Progression-free survival (PFS) was defined as the period between regorafenib initiation and disease progression or death due to any reason. Overall survival was defined as the period between regorafenib initiation and death due to any cause.
Results
A total of 23 patients were included in this study. Baseline characteristics are summarized in Table 1 . Of the 23 patients, 13 were male (56.5%). Median age was 62 (35-76) years. The rates of RAS wild-type and RASmutated tumor were 43.5% and 56.5%, respectively.
Eighteen patients (78.2%) received bevacizumab as first-line setting, whereas only five patients (28.8%) were given a prior anti-EGFR agent. The primary tumor was located on the left side in 17 patients (73.9%). The number of patients who underwent palliative surgery and metastasectomy was nine (39.1%) and five (21.7%), respectively. Most of the patients (91.3%) had a PS of 0-1 at the beginning of regorafenib therapy.
Regarding survival, median PFS was 3.02 (2.6-3.37) months and median OS was 6.4 (2.6-10.1) months for regorafenib therapy during a median follow-up of 5.4 (2.4-23.4) months (Figures 1 and 2 ). Overall survival was 37 (23.9-50.4) months. The presence of comorbidity was the only prognostic factor in univariate analysis; however, no factors were found to be associated with survival (Table 2 ).
Approximately 73.92% of patients were commenced on lower doses than standard. Starting dose of 160 mg was administered only in six patients. Dose modification was required in 69.56% of the patients (Table 3) . Dose escalation could be performed once in four patients and twice in two patients. Dose reduction was required once in seven patients and twice in three patients. Approximately 13.04% of patients discontinued treatment due to toxicity. The median number of treatment cycles was three (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The most common toxicities of any grade were hand-foot skin reaction (HFSR), fatigue, diarrhea, hypertension, mucositis and thrombocytopenia. Grade 3-4 toxicities were observed in seven patients (30.4%) with a descending order as follows, HFSR in 42.8%, fatigue in 28.5%, diarrhea in 14.28% and hypertension in 14.28% (Table 4) . 
Discussion
In the past 10 years, the availability of many drugs and the advent of new anti-angiogenic agents such as bevacizumab combined in standard regimens as first-line, second-line, or beyond progression setting have offered a considerable survival benefit with improved prognosis in patients with mCRC. Angiogenic regulation consists of a range of pathways and inhibition of a single target, such as VEGF, resulting in up-regulation of a diversity of pro-angiogenic factors (10), suggesting that a salvage treatment setting which includes a multi-kinase inhibitor with anti-angiogenic activity may be a plausible treatment option (11) . Regorafenib, a novel agent, is a multi-kinase inhibitor targeting a range of receptors including VEGF 1-3, PDGF, tyrosine receptor kinase-2, FGFR, BRAF, KIT, and RET (12).
Here, we aimed to evaluate the efficacy and safety of this new kinase inhibitor, although not including a representative sample. The median OS and median PFS in our study were 6.4 and 3.02 months, respectively. These findings are comparable to those reported in previous randomized studies. The CORRECT study was an international, randomized, and placebo-controlled phase-III trial including 760 patients who were (7), showing similar results to our findings. Another international phase 3 trial, CONCUR, which also confirmed the OS benefit of regorafenib in 204 Asian patients who were randomized 2:1 to receive either regorafenib or placebo (8.8 months vs 6.3 months, p=0.00016) (8), had a better median OS than that observed in our study. Median PFS durations for CORRECT and CONCUR trial were 1.9 and 3.2 months in the regorafenib arm, gaining only 0.2 and 1.5 months, respectively, compared to placebo group. The median PFS in our study was similar to that reported in CONCUR trial and higher than in the CORRECT trial. The REBECCA trial, a cohort of 1178 patients with mCRC, was an open-label and single-arm study of 654 patients (in full analyze) treated with regorafenib after a failure on standard therapies. This study demonstrated a median OS of 5.6 months and median PFS of 2.9 months with 12-month survival rate of 22% (9), indicating a similar median PFS but a lower median OS duration compared to those reported in our study, despite the higher number of patients starting with a lower dose of regorafenib in our study (73.9% in our study vs 18% in REBECCA).
The most common toxicities of any grade in our cohort were HFSR, fatigue, diarrhea, hypertension, mucositis and thrombocytopenia. HFSR, fatigue, diarrhea and hypertension were the most common grade 3-4 toxicities. This toxicity profile is substantially consistent with the adverse events reported in the REBECCA real-world cohort (9), CORRECT trial (7), and CONCUR trial (8) . Most adverse events were similar in the CONCUR (8) and CORRECT (7) trials, with the only exception of any-grade HFSR (74% vs 47%, respectively) and impaired liver function tests (37% vs 20%, respectively), which were more frequent in CONCUR trial (8) . The most common reason leading to drug-discontinuation in our study was the toxicity, similar to REBECCA cohort (9) . Most of the patients in our cohort (69.56%) required dose modifications and this was higher than those reported in CORRECT (7) (20% of patients required a dose reduction) and CONCUR trials (8) (40% of patients required a dose reduction). Compared to the REBECCA (9) cohort, a larger proportion in cohort started at a lower dose of regorafenib (18% vs 73,9%, respectively). Patients should be informed about the prophylaxis and management of regorafenibrelated adverse events prior to treatment to minimize the incidence of adverse events and to ensure that patients take full advantage of regorafenib treatment, thus optimizing treatment outcomes. Therefore, the most common adverse events should be discussed with the patient before the treatment.
The REBECCA real-world analysis (9) reported that high ECOG PS, a shorter time from the initial diagnosis of metastasis, starting at a lower initial dose of regorafenib, more than 3 metastatic sites, the presence of liver metastasis and KRAS mutation were the factors associated with shorter OS. However, there was no predictive factor associated with survival in our cohort, which might be due to the small sample size of our cohort.
So far, some studies have explored some biomarkers of efficacy for regorafenib, but no useful pretreatment biomarker in clinical practice has yet been determined (13, 14) . Indeed, there is no predictive biomarker to allow the selection of patients most likely to benefit from regorafenib (11). However, Komori et al. (15) reported that serum CA19-9 response was an early predictive marker of efficacy of regorafenib in mCRC.
The major limitation in our study was the small sample size, resulting in a suboptimal evaluation of outcome predictors in cox regression analysis. Hence, the results of this study should be interpreted with caution. In addition, selection bias and the absence of independent monitoring were other limitations inherent in retrospective studies, which might affect our results. Furthermore, identifying patients who will tolerate full-dose or a reduced dose of regorafenib is pretty important to optimize the study design. Nevertheless, our findings support the available data in the literature and provide useful information regarding the results of mCRC patients treated with regorafenib.
Conclusion
Regorafenib, a novel agent, is a multi-kinase inhibitor for use as monotherapy at last-line setting in mCRC. Although regorafenib shows a small but significant survival benefit in patients with mCRC who do not have any further treatment options after the failure over standard therapies, its toxicity profile along with the absence of predictive factors suggest a careful evaluation for the benefit/risk ratio before its use in clinical practice.
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